NOTE 9 — STOCK-BASED COMPENSATION PLANS

At our annual meeting of stockholders on October 29, 2014, our stockholders approved a new equity incentive plan (the “2014 Omnibus Plan”) under which awards of options and other stock-based awards may be made to employees, officers or non-employee directors of our Company. A total of 1,000,000 shares of Common Stock are authorized for grants of awards thereunder, which may be in the form of options, restricted stock, RSUs, stock appreciation rights (“SARs”), performance shares, performance units, Common Stock or dividends and dividend equivalents. As of June 29, 2017, there were 820,539 shares of Common Stock that remained authorized for future grants of awards, subject to the limitations set below. Under the terms of the Omnibus Plan, the total number of shares of Common Stock with respect to which options or SARs may be granted in any calendar year to any participant may not exceed 500,000 shares (this limit applies separately with respect to each type of award). Additionally, under the terms of the Omnibus Plan, for awards of restricted stock, RSUs, performance shares or other stock-based awards that are intended to qualify as performance-based compensation: (i) the total number of shares of Common Stock that may be granted in any calendar year to any participant may not exceed 250,000 shares (this limit applies separately to each type of award) and (ii) the maximum amount that may be paid to any participant for awards that are payable in cash or property other than Common Stock in any calendar year is $5,000. For fiscal 2017, the Board of Directors adopted an equity grant cap which further restricted the number of awards that could be made to any one participant or in the aggregate. The equity grant cap limited the number of awards to 250,000 awards to all participants and 20,000 awards to any one participant for the 2017 fiscal year. Except as set forth in the 2014 Omnibus Plan, RSUs have vesting periods of three years for awards to employees and one year for awards to non-employee members of the Board of Directors. Recipients of RSUs have the option to defer receipt of vested shares until a specified later date, typically soon after separation from the Company. The exercise price of stock options is determined as set forth in the 2014 Omnibus Plan by the Compensation Committee of our Board of Directors, and has to be at least the fair market value of the Common Stock on the date of grant. Except as set forth in the 2014 Omnibus Plan, stock options expire upon termination of employment or directorship, as applicable. Stock options granted under the 2014 Omnibus Plan are exercisable 25% annually commencing on the first anniversary date of grant and became fully exercisable on the fourth anniversary date of grant. Options generally will expire no later than ten years after the date on which they were granted. We issue new shares of Common Stock upon exercise of stock options.

We determine the fair value of stock option awards using the Black-Scholes option-pricing model; however, there were no options granted in fiscal 2017, fiscal 2016 or fiscal 2015.

The following is a summary of stock option activity for the year ended June 29, 2017:


	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding at June 30, 2016		9,500		$	8.78
Granted		—			—
Exercised		(7,500	)		8.40
Forfeited		—			—

Outstanding at June 29, 2017		2,000		$	10.24		2.06	$	105

Exercisable at June 29, 2017		2,000		$	10.24		2.06	$	105

The following table summarizes the total intrinsic value of all options exercised and the total cash received from the exercise of options for the last three fiscal years:


	Year ended June 29, 2017		Year ended June 30, 2016		Year ended June 25, 2015
Total intrinsic value of options exercised	$	374	$	792	$	781
Total cash received from exercise of options	$	63	$	155	$	643

All options were fully vested as of June 30, 2016. Exercise prices for options outstanding as of June 29, 2017 ranged from $8.71 to $14.73.

The fair value of RSUs is generally determined based on the market price of our Common Stock on the date of grant. The fair value of RSUs granted for the years ended June 29, 2017, June 30, 2016 and June 25, 2015 was $2,773, $3,212 and $2,835, respectively.

The following is a summary of RSU activity for the year ended June 29, 2017:


Restricted Stock Units	Shares			Weighted- Average Grant- Date Fair Value
Outstanding at June 30, 2016		228,270		$	32.33
Granted		45,213			61.33
Vested		(68,426	)		27.91
Forfeited		(3,199	)		30.23

Outstanding at June 29, 2017		201,858		$	40.36

At June 29, 2017 there were 68,673 RSUs outstanding that were vested but deferred. At June 30, 2016 there were 58,561 RSUs outstanding that were vested but deferred. The non-vested RSUs at June 29, 2017 will vest over a weighted-average period of 1.2 years. The fair value of RSUs that vested for the years ended June 29, 2017, June 30, 2016 and June 25, 2015 was $1,910, $928 and $615, respectively.

The following table summarizes compensation cost charged to earnings for all equity compensation plans and the total income tax benefit recognized for the last three fiscal years:


	Year ended June 29, 2017		Year ended June 30, 2016		Year ended June 25, 2015
Compensation cost charged to earnings	$	2,504	$	2,489	$	1,952
Income tax benefit recognized		951		962		814

At June 29, 2017, there was $3,008 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under our stock-based compensation plans. We expect to recognize that cost over a weighted-average period of 1.2 years.